Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

183 results about "Oxindole" patented technology

Oxindole (2-indolone) is an aromatic heterocyclic organic compound. It has a bicyclic structure, consisting of a six-membered benzene ring fused to a five-membered nitrogen-containing ring. Oxindole is a modified indoline with a substituted carbonyl at the second position of the 5-member indoline ring.

Nitric oxide releasing oxindole prodrugs for anagesic, Anti-inflammatory and disease-modifying use

Nitric oxide releasing oxindole prodrugs are described which are useful in methods of treating or preventing pain, inflammation, fever, or gastrointestinal lesions in a patient in need of such treatment, or of modifying an inflammatory disease or condition by favorably affecting the outcome thereof in said patient, wherein there is administered to said patient a therapeutically effective amount of a compound of Formula (I): and pharmaceutically acceptable salts thereof. In preferred embodiments, X is a covalent bond; RA and RB are both hydrogen; n is the integer 4; Y is -O-; Z is -NO2; RC is a member selected from the group consisting essentially of 5-Cl and 5-F; RD is a member selected from the group consisting essentially of 6-Cl and 6-F; and RE is a member selected from the group consisting essentially of benzyl, 2-furyl, 2-thienyl, 5-chloro-2-thienyl and 5-trifluoromethyl-2-thienyl.
Owner:PFIZER INC +1

Thio-oxindole derivatives

This invention relates to methods of co-administering compounds of formula 1 which are agonists of the progesterone receptor which have the general structure: wherein: R1, R2, R3, R4, R5 and Q1 are as defined herein, or a pharmaceutically acceptable salt thereof, with estrogen, an estrone, or an estrogen receptor agonist for contraception, hormone replacement therapy, or treating progesterone-related carcinomas and adenocarcinomas.
Owner:WYETH LLC

Oxindole compounds and their uses as therapeutic agents

This invention is directed to oxindole compounds that are useful for the treatment and / or prevention of sodium channel-mediated diseases or conditions, such as pain. Pharmaceutical compositions comprising the compounds and methods of using the compounds are also disclosed.
Owner:XENON PHARMACEUTICALS INC

Use

The present invention relates to a new use of oxindole derivatives of formula I, as a free base or pharmaceutically acceptable salts thereof, in the manufacture of a medicament for the prevention and / or treatment of dementia related diseases, Alzheimer's Disease and conditions associated with glycogen synthase kinase-3. Formula (I) wherein R1, R2, R3, ring Z, m and n are as defined as in claim 1. The present invention further relates to a method of prevention and / or treatment of dementia related diseases, Alzheimer's Disease and conditions associated with glycogen synthase kinase-3, as well as a pharmaceutical composition for said use.
Owner:ASTRAZENECA AB

Process for preparing 2-oxindoles and N-hydroxy-2-oxindoles

The present invention provides a processes, having practical utility, for preparing 2-oxindoles, N-hydroxy-2-oxindoles, or mixtures thereof comprising: catalytically hydrogenating a 2-nitroarylmalonate diester to produce a 2-(N-hydroxyamino)arylmalonate diester, a 2-aminoarylmalonate diester, or mixtures thereof as a first reaction intermediate; cyclizing, by intramolecular aminolysis of one ester group, the first reaction intermediate to produce a N-hydroxy-2-oxindole-3-carboxylate ester, 2-oxindole-3-carboxylate ester, or mixtures thereof as a second reaction intermediate; and hydrolyzing and decarboxylating the remaining ester group of the second reaction intermediate to produce the N-hydroxy-2-oxindole, the 2-oxindole, or mixtures thereof, wherein the cyclization reaction and the hydrolysis and decarboxylation reaction are conducted in situ with the catalytic hydrogenation reaction without isolation of said reaction intermediates.
Owner:CATALYTICA PHARMA

Process for preparing 3,3-disubstituted oxindoles and thio-oxindoles

Methods for preparing oxindole and thio-oxindole compounds are provided, which compounds are useful as precursors to useful pharmaceutical compounds. Specifically provided are methods for preparing 5-pyrrole-3,3-oxindole compounds and 5-(7-fluoro-3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-5-yl)-1-methyl-1H-pyrrole-2-carbonitrile. Also provided are methods for preparing iminobenzo[b]thiophene and benzo[b]thiophenone compounds.
Owner:WYETH LLC

Thio-oxindole derivatives

This invention relates to compounds which are agonists of the progesterone receptor which have the general structure: wherein:R1, R2, R3, R4, R5 and Q1 are as defined herein, or a pharmaceutically acceptable salt thereof, as well as methods of using these compounds to induce contraception or treat progesterone-related carcinomas and adenocarcinomas.
Owner:WYETH LLC

New Substituted Oxindole Derivative 352

The present invention relates to a new compound of formula (I)6-(5-cyano-2-hydroxy-1H-indol-3-yl)pyridine-3-carboxylic acid or a pharmaceutically acceptable salt thereof, in an essentially pure and isolated form, pharmaceutical formulations containing said compounds, to the use of said active compounds in therapy, and methods of prevention and / or treatment of conditions associated with glycogen synthase kinase-3 related disorders, comprising administering to a mammal, including human in need of such prevention and / or treatment, a therapeutically effective amount of said compound, as well as a process for preparing said compound.
Owner:ASTRAZENECA AB

Spiro-oxindole mdm2 antagonists

Provided herein are compounds, compositions, and methods in the field of medicinal chemistry. The compounds and compositions provided herein relate to spiro-oxindoles which function as antagonists of the interaction between p53 and MDM2, and their use as therapeutics for the treatment of cancer and other diseases.
Owner:RGT UNIV OF MICHIGAN

Spiro-oxindole mdm2 antagonists

Provided herein are compounds, compositions, and methods in the field of medicinal chemistry. The compounds and compositions provided herein relate to spiro-oxindoles which function as antagonists of the interaction between p53 and MDM2, and their use as therapeutics for the treatment of cancer and other diseases.
Owner:RGT UNIV OF MICHIGAN +1

Synthetic methods for spiro-oxindole compounds

This invention is directed to methods of preparing certain spiro-oxindole derivatives, which are useful for the treatment and / or prevention of sodium channel-mediated diseases or conditions, such as pain.
Owner:PACIRA THERAPEUTICS INC

Spiro-oxindole-derivatives as sodium channel blockers

This invention is directed to spiro-oxindole compounds of formulas (I), (II), (III), as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment and / or prevention of sodium channel-mediated diseases or conditions, such as pain.
Owner:XENON PHARMACEUTICALS INC

Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents

This invention is directed to pharmaceutical compositions for topical administration to a mammal, wherein the pharmaceutical compositions comprise a spiro-oxindole compound, as an enantiomer, a racemate or a non-racemic mixture, or a pharmaceutically acceptable salt thereof. These pharmaceutical compositions are useful for the treatment and / or prevention of sodium channel-mediated diseases or conditions.
Owner:PACIRA THERAPEUTICS INC

Methods of treating skin disorders using thio-oxindole derivatives

The present invention provides methods of treating skin disorders includes delivering to a mammal a composition containing a compound of formula I, or tautomers thereof, in a regimen, wherein formula I is:and wherein R1–R5 and Q1 are defined as described herein. Specifically, methods for treating acne, hirsutism, and a composition for conditioning the skin are described.
Owner:WYETH LLC

Spiro-oxindole compounds and their use as therapeutic agents

This invention is directed to spiro-oxindole compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment and / or prevention of sodium channel-mediated diseases or conditions, such as pain.
Owner:XENON PHARMACEUTICALS INC

Tricyclic spiro-oxindole derivatives and their uses as therapeutic agents

This invention is directed to tricyclic spiro-oxindole derivatives of formula (I), wherein j, k, m, n, w, q, Y, Q, X, R1, R2 and R3 are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, which are useful for the treatment and / or prevention of sodium channel-mediated diseases or conditions, such as pain. Pharmaceutical compositions comprising the compounds and methods of preparing and using the compounds are also disclosed.
Owner:XENON PHARMACEUTICALS INC

Spiro-oxindole MDM2 antagonists

Provided herein are compounds, compositions, and methods in the field of medicinal chemistry. The compounds and compositions provided herein relate to spiro-oxindoles which function as antagonists of the interaction between p53 and MDM2, and their use as therapeutics for the treatment of cancer and other diseases.
Owner:RGT UNIV OF MICHIGAN +2

Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain

This invention is directed to methods of using spiro-oxindole compounds of formula (I): wherein j, k, m, Q, X, R1, R2a, R2b, R2c, R2d and R3 are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, N-oxide, solvate or prodrug thereof, for the treatment and / or prevention of sodium channel-mediated diseases or conditions, such as pain.
Owner:XENON PHARMACEUTICALS INC

Method for preparing tricarbazole materials from aryl oxindole in one step

The invention provides a method for preparing tricarbazole materials from aryl oxindole in one step. The method utilizes aryl oxindole as a raw material, and directly obtains tricarbazole compounds through one-step synthesis under the condition that phosphorus oxychloride is used as a dehydrating agent. The method solves the problems that methods for synthesizing tricarbazole compounds in the prior art have long steps, and there is only one single way for introducing substituents into tricarbazole compounds. The obtained compound can be hopefully used for organic light emitting diodes.
Owner:NANJING UNIV OF TECH

Use of spiro-oxindole compounds as therapeutic agents

This invention is directed to methods of using spiro-oxindole compounds of formula (I): wherein k, j, Q, R1, R2a, R2b, R2c, R2d, R3a, R3b, R3c, and R3d are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the treatment and / or prevention of hypercholesterolemia, benign prostatic hyperplasia, pruritis and cancer.
Owner:XENON PHARMACEUTICALS INC

Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents

This invention is directed to asymmetric syntheses of certain spiro-oxindole derivatives, which are useful for the treatment and / or prevention of sodium channel-mediated diseases or conditions, such as pain.
Owner:PACIRA THERAPEUTICS INC

Spiro-oxindole mdm2 antagonists

InactiveUS20120122947A1Improve anti-tumor activityGreat clinical benefitBiocideOrganic chemistryDiseaseMedicine
Provided herein are compounds, compositions, and methods in the field of medicinal chemistry. The compounds and compositions provided herein relate to spiro-oxindoles which function as antagonists of the interaction between p53 and MDM2, and their use as therapeutics for the treatment of cancer and other diseases.
Owner:RGT UNIV OF MICHIGAN +2

Oxindole hydrazide modulators of protein tyrosine phosphatases (ptps)

The present invention is related to the use of oxindole hydrazide derivatives of formula (I) for the treatment and / or prevention of metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type I and / or II, inadequate glucose tolerance, insulin resistance, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, obesity, polycystic ovary syndrome (PCOS). In particular, the present invention is related to the use of oxindole hydrazide derivatives of formula (I) to modulate, notably to inhibit the activity of PTPs, in particular of PTP1B, TC-PTP, SHP and GLEPP-1. The present invention is furthermore related to novel oxindole hydrazide derivatives and method of preparation thereof.(I).
Owner:MERCK SERONO SA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products